Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
2023 · Cancers · 66 citations
https://doi.org/10.3390/cancers15030767
B
Beatrice Taurelli Salimbeni
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
56
Papers
449
Citations
10
h-index
11
i10-index
Beatrice Taurelli Salimbeni is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 10, co-authored 48 publications.
ORCID: 0000-0002-7345-4148Papers by this author
worksImmune and gene-expression profiling in estrogen receptor low and negative early breast cancer
2024 · JNCI Journal of the National Cancer Institute · 27 citations
https://doi.org/10.1093/jnci/djae178
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
2023 · Critical Reviews in Oncology/Hematology · 20 citations
https://doi.org/10.1016/j.critrevonc.2023.104148
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
2024 · ESMO Open · 8 citations
https://doi.org/10.1016/j.esmoop.2024.103731
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer
2025 · JAMA Network Open · 8 citations
https://doi.org/10.1001/jamanetworkopen.2024.61067
Molecular tumor board in patients with metastatic breast cancer
2024 · Breast Cancer Research and Treatment · 7 citations
https://doi.org/10.1007/s10549-024-07535-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat